2019
Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod
Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports 2019, 9: 8572. PMID: 31189943, PMCID: PMC6561945, DOI: 10.1038/s41598-019-42784-9.Peer-Reviewed Original ResearchConceptsBreast cancer skin metastasesBreast cancer metastasisSkin metastasesImmune responsePost-treatment tumor samplesCancer metastasisReceptor 7 agonistStrong T-helperDurable clinical responsesImmune effector functionsBasal cell carcinomaRobust immune responseTopical imiquimodClinical responseT helperTumor rejectionCell carcinomaCytotoxic functionTranscriptomic profilesTumor regressionClinical trialsAntigen presentationT cellsImiquimodTumor destruction
2017
Identification of differentially expressed genes associated with clinical response after treatment of breast cancer skin metastases with imiquimod.
Rozenblit M, Heguy A, Chiriboga L, Loomis C, Darvishian F, Egeblad M, Shao Y, Adams S. Identification of differentially expressed genes associated with clinical response after treatment of breast cancer skin metastases with imiquimod. Journal Of Clinical Oncology 2017, 35: e12541-e12541. DOI: 10.1200/jco.2017.35.15_suppl.e12541.Peer-Reviewed Original ResearchBreast cancer skin metastasesSkin metastasesClinical responseImiquimod treatmentInnate immunityNK cellsT cellsB cellsToll-like receptor 7 agonistAnti-tumor immune responseER/PR statusPanCancer Immune Profiling PanelUpregulation of genesReceptor 7 agonistNK cell functionImmune Profiling PanelPossible combination therapiesUpregulation of TNFGene expression changesActivation of lymphocytesExpression changesTop upregulated genesPrediction of responseIL-17Non responders